Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma

Fig. 5

Nomogram to predict survival probability of GBM patients. A Nomogram combining risk score with WHO grade, IDH status, 1p/19q codeletion, gender, age and primary therapy outcome. B-D Calibration plots for predicting 1-, 3-, and 5-year OS of GBM patients. E The combining of 1-, 3-, and 5-year OS of GBM patients. F The ROC curves reveal the survival using the risk score

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us